论文部分内容阅读
目的观察盐酸埃克替尼交替化疗治疗晚期非小细胞肺癌EGFR未知患者的近期疗效及不良反应。方法将本院肿瘤科2012年3月至2013年5月收治EGFR未知晚期非小细胞肺癌患者42例分为治疗组与对照组,均予吉西他滨联合顺铂方案化疗,治疗组加用口服盐酸埃克替尼125mg,3次/d,D15-28,两周期后即按RECIST1.1标准评价疗效,稳定及以上者均视为有效,观察近期疗效、KPS评分改善率、毒副反应等指标。结果 42例患者均治疗2周期后评价,其中治疗组完全缓解(CR)2例,部分缓解(PR)11例,疾病稳定(SD)4例,疾病进展(PD)2例,客观缓解率(ORR)为68.42%,疾病控制率(DCR)89.47%;对照组完全缓解(CR)1例,部分缓解(PR)7例,疾病稳定(SD)9例,疾病进展(PD)6例,客观缓解率(ORR)为34.78%,疾病控制率(DCR)65.21%。结果显示治疗组近期治疗效果优于对照组,提高患者生存质量,毒副反应骨髓抑制、恶心呕吐及腹泻反应与化疗相同,而口服埃克替尼后增加了皮疹反应,但因反应较轻,均能耐受。结论分子靶向药物盐酸埃克替尼交替化疗对晚期NSCLC有显著疗效,提高了疾病控制率及生存质量。
Objective To observe the short-term curative effect and side effects of the alternating chemotherapy of imatinib hydrochloride in patients with advanced non-small cell lung cancer (EGFR) unknown. Methods Forty-two patients with advanced non-small cell lung cancer with unknown EGFR from March 2012 to May 2013 in our hospital were divided into treatment group and control group, and received gemcitabine plus cisplatin regimen. The treatment group was treated with oral hydrochloric acid Ketinib 125mg, 3 times / d, D15-28, after two cycles according to RECIST1.1 standard evaluation of efficacy, stability and above are considered as effective, observe the short-term efficacy, KPS score improvement rate, toxicity and other indicators. Results 42 patients were evaluated after 2 cycles of treatment, including 2 CR cases, 11 PR cases, 4 SD cases and 2 PD cases. The objective response rate was ORR was 68.42% and DCR was 89.47%. The control group had complete remission (CR) in 1 case, partial remission (PR) in 7 cases, stable disease (SD) in 9 cases and disease progression (PD) in 6 cases. The response rate (ORR) was 34.78% and the disease control rate (DCR) was 65.21%. The results showed that the treatment group is better than the control group in the short term. The patients’ quality of life is improved. The bone marrow suppression, nausea, vomiting and diarrhea are the same as those of the chemotherapy, but the rash reaction is increased after the oral administration of icitidine. However, Can tolerate. Conclusion The molecularly targeted drug icotinib alternating chemotherapy has a significant effect on advanced NSCLC and improves disease control rate and quality of life.